Display options
Cite
Evans ME, Shenfield GM, Paterson JW. The clinical pharmacology of salmefamol. Br J Clin Pharmacol. 1974;1(5):391-7doi: 10.1111/j.1365-2125.1974.tb00275.x.
Evans, M. E., Shenfield, G. M., & Paterson, J. W. (1974). The clinical pharmacology of salmefamol. British journal of clinical pharmacology, 1(5), 391-7. https://doi.org/10.1111/j.1365-2125.1974.tb00275.x
Evans, M E, et al. "The clinical pharmacology of salmefamol." British journal of clinical pharmacology vol. 1,5 (1974): 391-7. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00275.x
Evans ME, Shenfield GM, Paterson JW. The clinical pharmacology of salmefamol. Br J Clin Pharmacol. 1974 Oct;1(5):391-7. doi: 10.1111/j.1365-2125.1974.tb00275.x. PMID: 22454916; PMCID: PMC1402468.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 1974 Oct;1(5):391-7. doi: 10.1111/j.1365-2125.1974.tb00275.x.

The clinical pharmacology of salmefamol.

British journal of clinical pharmacology

M E Evans, G M Shenfield, J W Paterson

Affiliations

  1. Asthma Research Council Clinical Pharmacology Unit, Department of Medicine, Cardiothoracic Institute, Brompton, London.

PMID: 22454916 PMCID: PMC1402468 DOI: 10.1111/j.1365-2125.1974.tb00275.x

Abstract

1 The absorption, excretion and metabolism of [(3)H]-salmefamol, a new sympathomimetic bronchodilator drug, have been studied in asthmatic patients. 2 Following oral administration of 1 or 2 mg to four patients the drug was well absorbed, peak plasma levels occurring from 0.6-2.0 h after administration. An improvement in forced expiratory volume in 1 s (FEV(1)) (ranging from 12-50% above baseline) was seen. 3 Following aerosol administration of 0.22-0.34 mg to four patients a rapid rise in FEV(1) was seen (range 26-117%). The plasma and urinary pictures following this route were similar to those seen after oral administration, suggesting that the majority of the dose was swallowed. 4 Very little free salmefamol was found in plasma or urine, the majority being present as metabolites. Urinary radioactivity was mainly present in the form of sulphate conjugates of at least two compounds, one of which was salmefamol. The other compound has not been identified but it is suggested that it may be an active metabolite.

References

  1. Br J Pharmacol. 1973 Sep;49(1):153P-154P - PubMed
  2. Br J Pharmacol. 1972 Nov;46(3):458-72 - PubMed
  3. Nature. 1968 Aug 24;219(5156):861-2 - PubMed
  4. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):861-7 - PubMed
  5. Br Med J. 1971 Mar 20;1(5750):637-9 - PubMed
  6. Thorax. 1973 Mar;28(2):124-8 - PubMed
  7. Br Med J. 1971 Oct 16;4(5780):139-42 - PubMed
  8. Acta Allergol. 1972 Feb;27(1):22-6 - PubMed
  9. Xenobiotica. 1972 Jul;2(4):363-73 - PubMed
  10. Br J Pharmacol. 1971 Oct;43(2):466P-467P - PubMed

Publication Types